Jing Yang , Bin Ren , Haobin Cai , Wei Xiong , Jie Feng , Qingdeng Fan , Zongheng Li , Lin Huang , Chenggong Yan , Yan Li , Chaomin Chen , Zheyu Shen
{"title":"Cyclic catalysis of intratumor Fe3+/2+ initiated by a hollow mesoporous iron sesquioxide nanoparticle for ferroptosis therapy of large tumors","authors":"Jing Yang , Bin Ren , Haobin Cai , Wei Xiong , Jie Feng , Qingdeng Fan , Zongheng Li , Lin Huang , Chenggong Yan , Yan Li , Chaomin Chen , Zheyu Shen","doi":"10.1016/j.biomaterials.2024.122793","DOIUrl":null,"url":null,"abstract":"<div><p>Numerous nanoparticles have been utilized to deliver Fe<sup>2+</sup> for tumor ferroptosis therapy, which can be readily converted to Fe<sup>3+</sup> <em>via</em> Fenton reactions to generate hydroxyl radical (•OH). However, the ferroptosis therapeutic efficacy of large tumors is limited due to the slow conversion of Fe<sup>3+</sup> to Fe<sup>2+</sup> <em>via</em> Fenton reactions. Herein, a strategy of intratumor Fe<sup>3+/2+</sup> cyclic catalysis is proposed for ferroptosis therapy of large tumors, which was realized based on our newly developed hollow mesoporous iron sesquioxide nanoparticle (HMISN). Cisplatin (CDDP) and Gd-poly(acrylic acid) macrochelates (GP) were loaded into the hollow core of HMISN, whose surface was modified by laccase (LAC). Fe<sup>3+</sup>, CDDP, GP, and LAC can be gradually released from CDDP@GP@HMISN@LAC in the acidic tumor microenvironment. The intratumor O<sub>2</sub> can be catalyzed into superoxide anion (O<sub>2</sub>•<sup>-</sup>) by LAC, and the intratumor NADPH oxidases can be activated by CDDP to generate O<sub>2</sub>•<sup>-</sup>. The O<sub>2</sub>•<sup>-</sup> can react with Fe<sup>3+</sup> to generate Fe<sup>2+</sup>, and raise H<sub>2</sub>O<sub>2</sub> level <em>via</em> the superoxide dismutase. The generated Fe<sup>2+</sup> and H<sub>2</sub>O<sub>2</sub> can be fast converted into Fe<sup>3+</sup> and •OH <em>via</em> Fenton reactions. The cyclic catalysis of intratumor Fe<sup>3+/2+</sup> initiated by CDDP@GP@HMISN@LAC can be used for ferroptosis therapy of large tumors.</p></div>","PeriodicalId":254,"journal":{"name":"Biomaterials","volume":"313 ","pages":"Article 122793"},"PeriodicalIF":12.8000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomaterials","FirstCategoryId":"5","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0142961224003272","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, BIOMEDICAL","Score":null,"Total":0}
引用次数: 0
Abstract
Numerous nanoparticles have been utilized to deliver Fe2+ for tumor ferroptosis therapy, which can be readily converted to Fe3+via Fenton reactions to generate hydroxyl radical (•OH). However, the ferroptosis therapeutic efficacy of large tumors is limited due to the slow conversion of Fe3+ to Fe2+via Fenton reactions. Herein, a strategy of intratumor Fe3+/2+ cyclic catalysis is proposed for ferroptosis therapy of large tumors, which was realized based on our newly developed hollow mesoporous iron sesquioxide nanoparticle (HMISN). Cisplatin (CDDP) and Gd-poly(acrylic acid) macrochelates (GP) were loaded into the hollow core of HMISN, whose surface was modified by laccase (LAC). Fe3+, CDDP, GP, and LAC can be gradually released from CDDP@GP@HMISN@LAC in the acidic tumor microenvironment. The intratumor O2 can be catalyzed into superoxide anion (O2•-) by LAC, and the intratumor NADPH oxidases can be activated by CDDP to generate O2•-. The O2•- can react with Fe3+ to generate Fe2+, and raise H2O2 level via the superoxide dismutase. The generated Fe2+ and H2O2 can be fast converted into Fe3+ and •OH via Fenton reactions. The cyclic catalysis of intratumor Fe3+/2+ initiated by CDDP@GP@HMISN@LAC can be used for ferroptosis therapy of large tumors.
期刊介绍:
Biomaterials is an international journal covering the science and clinical application of biomaterials. A biomaterial is now defined as a substance that has been engineered to take a form which, alone or as part of a complex system, is used to direct, by control of interactions with components of living systems, the course of any therapeutic or diagnostic procedure. It is the aim of the journal to provide a peer-reviewed forum for the publication of original papers and authoritative review and opinion papers dealing with the most important issues facing the use of biomaterials in clinical practice. The scope of the journal covers the wide range of physical, biological and chemical sciences that underpin the design of biomaterials and the clinical disciplines in which they are used. These sciences include polymer synthesis and characterization, drug and gene vector design, the biology of the host response, immunology and toxicology and self assembly at the nanoscale. Clinical applications include the therapies of medical technology and regenerative medicine in all clinical disciplines, and diagnostic systems that reply on innovative contrast and sensing agents. The journal is relevant to areas such as cancer diagnosis and therapy, implantable devices, drug delivery systems, gene vectors, bionanotechnology and tissue engineering.